Patients with inflammatory bowel disease [IBD] may develop, similarly to individuals from general population, rare cases of human papilloma virus [HPV]-related anal canal squamous cell carcinoma [SCC] and intra-epithelial precursor lesions, as well as very rare cases of anal canal adenocarcinoma. Patients with chronic perianal Crohn's disease [CD] are at substantial risk of developing SCC or adenocarcinoma from the fistula-lining epithelium, as well as SCC or adenocarcinoma arising from chronic anorectal ulcerations or strictures. Based on this lesion stratification, we provide in this review tailored incidence estimates and we propose an IBD-specific classification of all types of anal neoplasia that may occur in patients with IBD. After reviewing putative carcinogenesis of all types of neoplasia, we conclude that HPV vaccination could reduce the incidence of HPV-related lesions, although an anal screening programme related to these lesions is not mandatory on the sole basis of IBD. By contrast, we point out that all patients with chronic perianal CD should be explored in depth, including biopsies under anaesthesia and fistula curettage when necessary, in case of any change in anal symptoms ─in particular new, increasing, unexplained pain. Finally, we conclude that there is an urgent need for elaborating and evaluating surveillance algorithms in patients with chronic perianal CD, in order to avoid cancers with late diagnosis and poor prognosis.
Introduction
Crohn's disease [CD] and ulcerative colitis [UC] , collectively referred to as inflammatory bowel disease [IBD] , are immune-mediated diseases of unknown origin which occur in genetically susceptible hosts. They are characterised by lifelong relapsing intestinal inflammation, requiring the long-term use of immunosuppressive therapy in an increasing proportion of patients. 1, 2 An excess risk of colorectal neoplasia is well established in patients with extensive colitis and/or primary sclerosing cholangitis, both in UC and in CD. 3 The same is true for small bowel neoplasia in patients with ileal CD. 4 Less is known about epidemiology and natural history of various forms of anal neoplasia that may occur in patients with IBD. Epidemiology, carcinogenesis, and perspectives of prevention of anal neoplasia in IBD are addressed in this review. We also propose a pathological classification of anal neoplasia subtypes in IBD.
Anatomy and pathology
The anal canal is a short [3-4 cm ] segment distal to the rectum. The anatomical definition of the anal canal has evolved over time. It is currently considered by surgeons and physiologists that the proximal border of the anal canal is the anorectal ring [a palpable structure at the level of the puborectalis muscle], and the distal border is the anal verge. 5 The epithelial tissues lining the anal canal mucosa from proximal to distal include successively: 1] colorectallike columnar epithelium immediately distal to the anorectal ring; 2] stratified columnar epithelium [similar to transitional epithelium of the genitourinary tract] that ends at the dentate line; 3] non-keratinised squamous cell epithelium extending from the dentate line to the anal verge. Beyond the anal verge lies a hair-bearing squamous epithelium similar to cutaneous tissue. The five first centimetres of this zone, distal to the anal verge, are defined as the perianal skin.
Classification of anal tumours
Histological classification of anal tumours proposed by the World Health Organization [ Table 1 ] is based on the originating cell types of the tumours [epithelial tumours, mesenchymal tumours, and secondary tumours]. 6 Descriptive pathological criteria of the various subtypes of tumours and their staging have been recently updated. 5 The most frequent tumours are squamous epithelial tumours, followed by adenocarcinomas and malignant melanomas. Anal neoplasia subtypes are defined by their histological and immunophenotypical profile and by the anatomical location they derive from. In addition, emerging epidemiological and pathophysiological data strongly suggest that some subtypes of anal canal malignancies are specifically encountered in patients with IBD [see Epidemiology, Section 4]. We propose here a classification of anal neoplasia that may occur in patients with IBD [ Table 2 and Figure 1 ]. SQ-a lesions refer to squamous cell neoplasia of the anal canal, 7 including SCC and their intraepithelial precursor lesions, typically originating from the squamous non-keratinised epithelium or, rarely, from the transitional zone epithelium. Morphologically heterogeneous, the majority of SQ-a cancers have a mixed appearance of squamous, basaloid, and glandular features. 5 GL-a lesions refer to adenocarcinomas and intra-epithelial precursor lesions of the anal canal, which may evolve from the anal glands situated along the dentate line, transitional zone, or colorectaltype epithelium immediately distal to the anorectal ring. Neoplastic transformation arising from fistulas related to CD [SQ-f and GL-f lesions] may lead to either SCC or adenocarcinomas. Lower rectal tumours [GL-r lesions] may secondarily infiltrate the anal canal, therefore posing a diagnostic challenge with anal canal-derived cancers [GL-a lesions]. Pathological identification of an anal glandular lesion or the presence of at least 50% of the tumour distal to the dentate line has been suggested as a diagnostic criterion to differentiate adenocarcinoma of the anal canal from lower rectal cancer adenocarcinoma. However, this has not been fully validated. 8 SQ-p and GL-p neoplasia arises from the perianal skin, and must not be related to an underlying fistula. OT tumours encompass other anal neoplastic lesions that are less frequent. They include malignant melanomas, neuroendocrine tumours, other rare primary tumours, and anal metastases originating from the primary cancer of another organ.
Epidemiology of anal cancer
Anal cancers account for 1-2% of digestive cancers. SCCs and adenocarcinomas represent the vast majority of anal cancers. SCCs account for 80-85% of all anal cancers. Table 3 ], after a progressive increase from the mid 1970s.
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As a result of the higher prevalence of anal oncogenic human papilloma virus [HPV] infection in females than in males [see the carcinogenesis section], women are twice as likely affected by anal SCC. 12, 13 The incidence of SCC is significantly increased in HIVnegative men who have sex with men.
14 HIV-infected persons have the highest prevalence of HPV infection. 14, 15 Post-transplantation immunosuppression also greatly increases the risk of HPV-related anal tumours with a prevalence of 6% of dysplastic changes on anal PAP smears and a standardised incidence ratio of 6 for anal cancer. 16, 17 Other risk factors for anal SCC include smoking, sexual behaviour [first sexual intercourse at an early age, multiple partners], receptive anal intercourse, presence of anal condylomata acuminate, and personal history of cervical, vulvar, or vaginal carcinoma. 
Adenocarcinoma
The incidence of anal and perianal adenocarcinoma is stable in Western countries and approximates 0.002 per 1000 patientyears. 9, 10 Among patients presenting with perianal adenocarcinomas, about half of the cases are primary glandular-derived cancers, mostly arising from perianal lesions of Paget's disease, and the other half are adenocarcinomas arising from fistulas. 18, 19 Carcinomas of the lower rectum extending into the anal canal have only been reported in case reports and small series in the general population. 20 
Patients with IBD

SCC
Population-based data on the incidence of SCC in IBD are lacking. In a systematic review that included 11 studies from referral centres [1940 to 2005] , the incidence of SCC was 0.02 per 1000 patient-years in patients with CD and 0.009 per 1000 patient-years in patients with UC, ie similar to that of the general population. 21 In this review, that excluded cancers arising from fistulas, females were much more often affected than males [17 females vs three males] and patients developed SCC on average at 42 years of age [27-80 years], which is notably earlier than in the general population 9,10 or in HIV-positive patients. Proposed classification of the most frequent forms of anal neoplasia that may occur in patients with inflammatory bowel disease. SQ-a lesions refer to anal canal squamous cell carcinoma and intra-epithelial squamous precursor lesions, typically originating from the squamous non-keratinised epithelium and rarely arising from the transitional zone epithelium. SQ-f lesions refer to fistula-related squamous cell carcinoma and intra-epithelial squamous precursor lesions. SQ-p lesions refer to perianal squamous cell carcinoma and intra-epithelial squamous precursor lesions with extension into the anal canal. GL-a lesions refer to anal canal adenocarcinoma and low/high grade dysplasia, typically originating from either the anal glands situated along the dentate line, or the transitional zone, or colorectal-type epithelium [immediately distal to the anorectal ring]. GL-f lesions refer to fistula-related adenocarcinoma and low/high grade dysplasia. GL-p lesions refer to perianal adenocarcinoma and low/high grade dysplasia with extension into the anal canal. GL-r lesions refer to lower rectum adenocarcinoma and low/high grade dysplasia with extension into anal canal. The anorectal ring is a palpable structure at the level of the rectopubalis muscle. 10 and Shiels MS et al. 9 The majority of the cases of anal SCC that develop in patients with CD are diagnosed in the context of long-standing CD [> 10 years] and underlying chronic perianal disease. Prevalence of anal HPV in the IBD population has not been reliably established [ Table 4 ]. 
Anal adenocarcinoma
There are no specific data in the population of patients with IBD on the incidence of adenocarcinoma primarily arising from the epithelium lining the anal canal [GL-a].
Malignant transformation of anal or perianal chronic lesions in CD
Malignancy arising from CD-associated perianal fistulas was first reported by Lightdale et al. in 1975 . 24 In a meta-analysis on the risk of intestinal cancer in CD from referral centre cohorts, the pooled incidence of CD fistula-related cancer was 0.2 per 1000 patientyears. 25 It is likely that most of the fistula-associated cancers taken into account in this systematic review originated from perianal fistulas rather than from other types of intestinal fistulas, but this point is not specifically mentioned. In the largest systematic review of malignant transformation of perianal fistulas in CD, 26 . Most reported fistulas were complex in nature, and 59% originated from the rectum rather than from the anal canal [ Figure 1 ].
Adenocarcinoma may also arise in irreversible chronic anorectal strictures in patients with CD [type sS2a and S2b lesions in the Cardiff classification of perianal CD]. 27 In a series of 102 patients with anorectal strictures, two patients [2%] developed anal adenocarcinoma in the follow-up. 28 In the context of adenocarcinoma developed from anorectal stricture, the distinction between lower rectum adenocarcinoma with extension to the anal canal and anal adenocarcinoma with extension to the lower rectum is often difficult.
Other cancers
The specific incidences and characteristics of other types of anal cancer [malignant melanoma, neuroendocrine tumours, lymphoma, metastases] in the IBD population are unknown.
Prognosis of anal cancers in IBD
Anal SCC in IBD has a poor prognosis, with a 37% 5-year survival rate according to the sole systematic review available. 21 In contrast, 5-year survival rate after diagnosis of anal SCC exceeds 60% in the general population. 22, 29 The relatively bad prognosis associated with anal SCC in the IBD population may be partly related to poor specificity of associated symptoms or difficulties in the diagnostic process. 30 In one series, only one out of four patients presented with symptoms leading to cancer diagnosis, whereas the remainder had their cancer diagnosed incidentally. 31 Furthermore, some patients require multiple biopsies and imaging studies before the diagnosis can be confirmed. 32 Consequently, the average time to diagnosis is 5.8 months for fistula-related anal cancer, compared with the median delay range of typical rectal cancer diagnosis of 10 to 26 weeks [cancer stage dependent]. 33 Anal adenocarcinoma demonstrates a more aggressive behaviour compared with anal SCC in the general population, 34 but this has not been studied in patients with IBD. Prognosis of cancers arising in CD perianal fistulas must be considered apart. In the review by Thomas et al., cancer was suspected at the first visit and confirmed with biopsy in only 20% of the patients. 26 Clinical examination without anaesthesia can be hampered by pain and strictures. 36 Even under anaesthesia, malignant cells may be missed by superficial biopsies. Although curettage and biopsies of fistulous tracts are strongly recommended, 35, 36 they are not possible in all cases. The prognosis of perianal fistula-associated cancers is poor, with a 4-year survival rate ranging among series from 30% 37 to 60%. High-risk oncogenic HPV DNA has been isolated in as much as 91% of anal carcinoma specimens, with HPV16, 18, 52, and 33 being the most frequent subtypes. [38] [39] [40] HPV infects keratinocytes and incorporates oncogenes E6 and E7 into the host genome. These oncogenes subsequently induce the degradation of p53 and inactivation of products of the retinoblastoma family, ultimately leading to chromosomal instability or microsatellite instability. 41, 42 Malignant transformation of anal squamous epithelium follows a dysplasia to neoplasia sequence. Table 4 . Unanswered questions in the field of anal cancer carcinogenesis and risk management in IBD.
Carcinogenesis of non-fistula related anal canal SCC
Are there specificities in the prevalence and serotype distribution of HPV infection in patients with IBD matched for other established risk factors of HPV infection [smoking status, sexual practices]? Does immunosuppressive therapy increase the risk of anal HPV-related SCC and intra-epithelial precursor lesions in patients with IBD and HPV infection? Is the excess risk of non-fistula related anal SCC in patients with CD at least partly related to local or systemic inflammation?
Carcinogenesis of anal canal adenocarcinoma
Does HPV infection play a role in carcinogenesis? Does chronic inflammation of anal mucosa in patients with CD play a role in carcinogenesis?
Carcinogenesis of fistula-related SCC and adenocarcinoma
What are the frequency and the role of HPV infection of the epithelial lining of fistulas in SCC and adenocarcinoma?
Surveillance of patients with CD and chronic perianal disease
What are the optimum frequency and modalities [among digital examination, anoscopy, MRI, examination under general anaesthesia] of surveillance? Which specific surveillance should be proposed to patients with painful anal examination and/or anorectal strictures?
HPV, human papilloma virus; IBD, inflammatory bowel disease; SCC, squamous cell carcinoma; CD, Crohn's disease; MRI, magnetic resonance imaging.
The role of the host immune system is important in protecting against HPV infection and development of HPV-related cancers. HIV-positive men, in particular those who have sex with men [MSM], have a frank excess risk of developing anal SCC and their intra-epithelial precursor lesions. 14, 15 This is attributed, at least partly, to a decreased immunosurveillance. 16, 17, 43 An HIV-induced immunosuppressed state as defined by low nadir CD4 T cell count has been associated, however inconsistently, with higher risk of intra-epithelial and invasive anal neoplasia. 13, 44, 45 Disruption in the mucosal integrity may also facilitate HPV viral infection of keratinocytes and consequently carcinoma. Higher rates of high-risk HPV infection in patients with fissure and fistulas suppose that disruption in the mucosal barrier provides HPV access to basal epithelial layers. 46 Similarly, disruption of epithelial tight junctions in HIV-infected hosts is supposed to facilitate oncogenic viral infection. 47 Little is known of anal canal adenocarcinoma genesis or whether it shares any carcinogenic pathways with colorectal neoplasia, or whether HPV infection plays a role. 48 
Anal cancer in IBD
Pathogenesis of IBD-related anal cancers is thought to be associated with disease-related mechanisms that include local and systemic chronic inflammation, HPV infection, decreased defensin function in CD, and drug-induced immunosuppression.
Anal canal SCC in IBD
Chronic inflammation potentially may promote HPV-associated anal SCC, but this statement is still more based on concepts than on experimental evidence. In general, local chronic inflammation involves multiple mediators including reactive species of oxygen and nitrogen, cytokines, chemokines, cyclooxygenase [COX], metalloproteinases, prostaglandins, and specific types of microRNAs that collectively induce, mostly via NF-kappaB, changes in the processes of proliferation, senescence, and cell death, as well as in mutation and methylation of DNA. 49 Local chronic inflammation as seen with cervicitis is associated with 1.9 higher risk of HPV-induced high-grade squamous intra-epithelial lesion and invasive cervical carcinoma. 50 Furthermore, epidemiological evidence suggests that chronic systemic inflammatory states such as systemic lupus erythematosus or rheumatoid arthritis also confer a higher risk of developing high-grade uterine cervix dysplastic lesions. 51 However, studies evaluating cervical dysplasia in the IBD population have conflicting results. 52, 53 Whether these findings can be extrapolated to HPV-induced anal cancer is unknown [ Table 4 ]. In addition to the potential promoting role of local inflammation, the question of reduced local immunity against HPV in the anal canal should be addressed. Defensins are also a major component of the innate immunity of the gut, where they are produced by Paneth's cells. It is established that the expressed levels of defensins in distal ileum are decreased in patients with CD, irrespective of the local level of inflammation. 54 Various human defensins have been shown to inhibit both cutaneous and mucosal HPV, are present in the genital mucosa, and act as a natural barrier against HPV. Whether defensins are present and functional in the anal canal, and if their function is reduced in patients with CD, should be addressed.
Prolonged exposure to immunosuppressive therapy in IBD may promote HPV-associated cervical dysplasia following a dysplasia-tocarcinoma sequence. According to a recent meta-analysis, prolonged exposure to immunosuppressive therapy in IBD could promote HPV-associated uterine cervix dysplasia and cancer (odds ratio [OR] = 1.34, 95% confidence interval[CI]: 1.23-1.46). 55 In one of the studies analysed, Hutfness et al. suggested an odds ratio for inducing 56 Nevertheless, when closely examining individual studies, evidence regarding cervical abnormalities attributable to thiopurines and anti-tumour necrosis factor [TNF] therapy is still lacking. 3, 57 The only study addressing the role of immunosuppressive therapy in IBD as a risk factor for anal neoplasia was negative, with no case of SCC or intra-epithelial precursor lesions in patients exposed to immunosuppressive therapy. 23 
Fistula-related SCC in CD
Cases of SCC of the anus in IBD have predominantly been reported in patients with active chronic perianal involvement. 25 It is speculated that local breaches of anal canal mucosa and epithelialisation of fistulous tracts may provide direct access of HPV infection to keratinocytes, leading to HPV-driven carcinogenesis. 21, 32 The proportion of HPV-associated cases of SCC developing specifically from perianal fistulas is unknown [ Table 4 ]. However, Frisch et al. tested for HPV 45 cases of SCC developed from sporadic anal fissure or fistula in the general population. 46 In this study, the presence of highrisk types of HPV was found in 94% of the cases of SCC.
Anal canal adenocarcinoma in IBD
Colitis-associated colorectal adenocarcinoma complicating IBD follows a specific dysplasia-carcinoma sequence, compared withsporadic colorectal adenocarcinoma. Chronic inflammation in IBD drives oxidative stress-induced DNA damage resulting in a field change of molecular alterations including activation of proto-oncogenes and silencing of tumour-suppressor genes. Complex interaction between host microbiota and mucosal cell receptors may further promote neoplasia. 58, 59 In the IBD population, anal adenocarcinoma most frequently develops in the context of longstanding local inflammation. 58, 59 This gives sense to the hypothesis that similar molecular alterations may be involved as colitis-associated colorectal cancer. 60 Whether HPV plays a role in carcinogenesis of anal adenocarcinoma is unknown [ Table 4 ].
Fistula-related adenocarcinoma in CD
Fistula-related adenocarcinoma of the anus is a distinct entity that may arise from the columnar epithelial lining of the fistula or alternatively through an epithelial-to-mesenchymal transition within a longstanding CD fistula. 61 In one study, immunophenotyping has differentiated true fistula-related adenocarcinomas from anal glandderived adenocarcinomas based on cellular markers. 62 The authors suggested that rectal-type mucosa might migrate into the fistula with subsequent malignant transformation. In another study, an adenomatous epithelialisation of a fistula tract was associated with a mucinous adenocarcinoma. 63 Whether HPV plays a role in carcinogenesis of fistula-related adenocarcinoma is unknown [ Table 4 ].
Management of the risk of anal cancer in IBD
In this section we rated the level of evidence of the literature supporting each suggestion according to the Oxford Centre for Evidencebased Medicine. 
. Prevention of HPV infection
Prophylactic quadrivalent vaccine against HPV types 6, 11, 16, and 18 has been available since 2006 and is highly effective for prevention of HPV-related genito-urinary lesions in both males and females. 65 Vaccination reduces the rate of high-grade anal intra-epithelial neoplasia related to high-risk HPV strains by 75% [per protocol analysis, at-risk non-HIV male patients]. 65 Based on efficacy in preventing cervical cancer, vaccination is currently recommended for all females of 11 or 12 years of age, and catch-up vaccination can be administered until the age of 26 years, according to the Advisory Committee on Immunization Practices. 66 This recommendation also extends to boys in the USA and in some European countries. In patients with IBD, the European Crohn's and Colitis Organisation recommends routine prophylactic HPV vaccination for both females and males according to national guidelines [EL2]. 67 Behavioural factors have also a role in the prevention of HPV infection. Cessation of cigarette smoking and safer sex practices are able to decrease the prevalence of HPV-infected individuals, 68 and could in turn decrease the incidence of risk of HPV-driven anal cancer in patients with IBD.
Anal SCC screening
Anal Pap smear can detect precancerous and intra-epithelial lesions that may lead to invasive anal carcinoma. As a screening tool, it is as sensitive in detecting anal cytological abnormalities in highrisk patients as it is for cervical cancer, and contributes in carefully selecting patients for high-resolution anoscopy. 69 To date, no studies have shown survival benefit in screening for anal cancer. However, many guidelines suggest anal cancer screening [including digital rectal examination and anal Pap smears or standard anoscopy] in highrisk HIV-positive individuals. 70 The risk of non-fistula related SCC in patients with UC is the same as in general population and does not justify an anal cancer screening programme in patients with IBD who are not specifically at high risk because of associated HIV infection or personal history of anogenital condyloma [EL5]. There is a mild increased risk of non-fistula related SCC in patients with CD, but the resulting absolute risk [0.02 per 1000 patient-years] remains very low and does not justify a routine anal cancer screening programme in patients without chronic perianal disease [EL5].
Early diagnosis of anal cancer and surveillance modalities in patients with chronic perianal CD
In patients with CD and chronic perianal fistulizing disease, the incidence of malignant transformation is 0.2 per 1000 patient-years, 25 as high as the risk of colorectal cancer in patients with CD without long-standing extensive colitis. 58 In addition, the risk of malignant transformation of chronic anorectal ulcerations and/or strictures is substantial. 28 This should be taken into account in the clinical management of patients with long-standing perianal disease. 3, 4, 26, 32, 71 6.2.1. Early diagnosis of anal cancer [ Figure 2 ] The key explanation of the usual delay in the diagnosis of malignant transformation of CD perianal fistulas is that most clinical symptoms potentially attributable to cancer and fissures or fistulas are the same. In addition, the development of an anorectal stricture may be a nonmalignant complication of a complex perianal CD as well as the pathological expression of a growing cancer. Devon et al. have reported in their series that all patients with fistula-related cancers had a significant history of increasing and/or intractable pain. 32 After reviewing previously reported series, the authors have pointed out that almost all patients with cancer experienced a change in the severity of pain or symptoms, such as discharge. It is now admitted that in patients with long-standing perianal CD, a change in symptoms, and particularly an unexplained pain, should always raise the suspicion of cancer. In this context, the yield of clinical examination is poor, leading to the diagnosis of cancer in a minority of patients. 26 Imaging techniques are also often inconclusive. In the series by Devon et 
Surveillance modalities
Although there is now a solid epidemiological rationale for a surveillance programme in order to detect early anal cancers in patients with long-standing perianal CD, the optimal frequency and modalities of surveillance are unknown. An expert consensus is needed in this field. In the meanwhile, common sense and existing literature suggest that the first recommended step could be the routine examination with perianal clinical examination, including digital rectal examination, followed by imaging techniques and biopsies [see above] when malignancy is suspected [EL5]. In patients with painful perianal examination or anorectal strictures, alternative surveillance algorithms should be developed and evaluated.
Conclusion
In patients with UC or CD without chronic perianal disease, most anal neoplasias are HPV-related SCC and their intra-epithelial precursor lesions; these are characterised by low incidence that could be reduced in the long term by the implementation of HPV vaccination programmes. Patients with chronic perianal CD are at substantial risk of anal canal-located or fistula-related SCC or adenocarcinoma, and anorectal stricture-related adenocarcinoma. Any change in the severity of anal symptoms, including any unexplained increasing pain, is important alarm signal that should lead to a diagnostic workup, including biopsy under anaesthesia and curettage of fistula tracts when appropriate. Given the late diagnosis and poor prognosis of fistula-associated and stricture-associated cancers, surveillance programmes aimed at early detection of asymptomatic lesions in patients with chronic perianal CD should be developed and validated.
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